Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP

Diabetes technology & therapeutics1 Apr 2007Cited by 24 (Europe PMC)

PMID17425446DOI10.1089/dia.2006.0013PepBankPUB-17425446

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialSafety outcome
In insulin-treated patients with type 2 diabetes, 29.5% reported nausea during pramlintide treatment, primarily mild to moderate.
In plain wordsIn patients with type 2 diabetes receiving pramlintide, nausea was primarily mild to moderate.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableNausea
Study
n = 166
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
Nausea
29.5%
pramlintide treatment
Source sentences
Summary
Nausea, primarily mild to moderate, was reported by 29.5% of patients (severe nausea in 2.4%).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544605
02HumanNon-randomized trialSafety outcome
In insulin-treated patients with type 2 diabetes, 2.4% reported severe nausea during pramlintide treatment.
In plain wordsIn patients with type 2 diabetes receiving pramlintide, severe nausea occurred in 2.4%.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSevere nausea
Study
n = 166
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
Severe nausea
2.4%
pramlintide treatment
Source sentences
Summary
Nausea, primarily mild to moderate, was reported by 29.5% of patients (severe nausea in 2.4%).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544606
03HumanNon-randomized trialSafety outcome
In insulin-treated patients with type 2 diabetes, severe hypoglycemia occurred at 0.04 events/patient-year during pramlintide treatment.
In plain wordsIn patients with type 2 diabetes receiving pramlintide, the reported severe low-glucose event rate was low.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSevere hypoglycemia
Study
n = 166
Outcome group
Adverse events · Metabolic and weight
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
Severe hypoglycemia rate
0.04 events/patient-year
pramlintide treatment
Source sentences
Summary
Rates of severe hypoglycemia were low (0.04 events/patient-year).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544607
04HumanNon-randomized trialEfficacy outcome
In insulin-treated patients with type 2 diabetes, weight fell by 2.8 kg during pramlintide treatment versus baseline.
In plain wordsIn patients with type 2 diabetes, weight fell during pramlintide treatment compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseWeight change
Study
n = 125
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
Weight change
−2.8 kg
6 months
Source sentences
Summary
Pramlintide treatment significantly reduced mean postprandial glucose excursions (P < 0.05) and weight (-2.8 kg; P < 0.05; n = 125).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544603
05HumanNon-randomized trialEfficacy outcome
In insulin-treated patients with type 2 diabetes, mealtime insulin doses fell by 10.3% during pramlintide treatment versus baseline.
In plain wordsIn patients with type 2 diabetes, insulin doses at meals fell during pramlintide treatment compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMealtime insulin dose
Study
n = 104
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
Mealtime insulin change
−10.3%
6 months
Source sentences
Summary
Glycemic benefits were achieved with lower mealtime insulin doses (-10.3%; P < 0.05; n = 104).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544604
06HumanNon-randomized trialEfficacy outcome
In insulin-treated patients with type 2 diabetes, A1C fell by 0.56% from baseline after pramlintide initiation and insulin adjustment.
In plain wordsIn patients with type 2 diabetes, A1C fell after pramlintide initiation and insulin adjustment compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseA1C change
Study
n = 59
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg · 6 monthsAs given in this study (human).
Measurements
A1C change
−0.56%
6 months
Source sentences
Summary
At 6 months, the change in A1C from baseline (8.3%) was -0.56% (P < 0.05; n = 59).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544601
07HumanNon-randomized trialEfficacy outcome
In insulin-treated patients with type 2 diabetes, pramlintide treatment reduced mean postprandial glucose excursions from baseline.
In plain wordsIn patients with type 2 diabetes, glucose rises after meals decreased during pramlintide treatment compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursions
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg · 6 monthsAs given in this study (human).
Source sentences
Summary
Pramlintide treatment significantly reduced mean postprandial glucose excursions (P < 0.05) and weight (-2.8 kg; P < 0.05; n = 125).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study, 166 insulin-treated patients with type 2 diabetes added pramlintide therapy (120 microg) during an initiation period in which mealtime insulin was reduced by 30-50%.
Summary · context
Endpoints included safety, as well as change in A1C, postprandial glucose, weight, insulin dose, and patient satisfaction following 6 months of pramlintide treatment.
Report a problemFND-1742544602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00108004

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

AstraZenecan = 400Apr 2003 to Jun 2005

Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 21 May 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.